New ABC transporters in multi-drug resistance

Expert Opinion on Therapeutic Targets

Volumn 4, Issue 5, 2000, Pages 561-580

  Bates, Susan E ^a   Robey, Robert ^a   Knutsen, Turid ^a   Honjo, Yasumasa ^a   Litman, Thomas ^a   Dean, Michael ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ABC transporters; drug resistance; MDR

Indexed keywords

EID: 33750430768     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.4.5.561     Document Type: Review

References (133)

1. DANO K: Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim. Biophys. Acta (1973) 323:466-483.
2. BECK WT, MUELLER TJ, TANZER LR: Altered surface membrane glycoproteins in vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res. (1979) 39:2070-2076.
3. BIEDLER JL RIEHM H: Cellular resistance to actinomy-cin D in Chinese hamster cells in vitro: cross-resistance, radioautographic and cytogenetic studies. Cancer Res. (1970) 30:1174-1184.
4. KARTNER N, RIORDAN JR, LING V: Cell surface P-glycoprotein associated with multidrugresistance in mammalian cell lines. Science (1983) 221:1285-1288.
5. GERMANN UA: P-glycoprotein-a mediator of multidrug resistance in tumour cells. Eur. J. Cancer (1996) 32A:927-944.
6. SHAROM FJ: Characterization and functional reconsti-tution of the multidrug transporter. J. Bioenerg. Biomembr. (1995) 27:15-22.
7. TSURUO T, IIDA H, TSUKAGOSHI S etal: Overcoming of vincristine resistance in P388 leukemia in vivoand in vitro through enhancing cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. (1981) 41:1967-1972.
8. BRADSHAW DM, ARCECI RJ: Clinical relevance of transmembrane drug efflux as a mechanism of multidrugresistance.J. Clin. Oncol. (1998) 16:3674-90.
9. FERRY DR, TRAUNECKER H, KERR DJ: Clinical trials of P-glycoprotein reversal in solid tumours. Eur. J. Cancer (1996) 32A: 1070-81.
10. TEW KD, HOUGHTON PJ, HOUGHTON JA: Preclinical and clinical modulation of anticancer drugs. CRC Press, Boca Raton, USA (1993).
11. HIGGINS CF: ABC transporters: from microorganisms to man. Ann. Rev. Cell. Biol. (1992) 8:67-113.
12. HIGGINS CF: The ABC of channel regulation. Cell (1995) 82:693-696.
13. HIGGINS CF, GALLAGHER MP, MIMMACK ML, PEARCE SR: A family of closely related ATP-binding subunits from prokaryotic and eukaryotic cells. Bioessays (1988) 8:111-116.
14. KLEIN I, SARKADI B, VARADI A: An inventory of the human ABC proteins. Biochim. Biophys. Acta (1999) 1461:237-262.
15. ALLIKMETS R, GERRARD B, HUTCHINSON A, DEAN M: Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. Hum. Mol. Genet (1996) 5:1649-1655.
16. SCHRIML LM, DEAN M: Identification of 18 mouse ABC genes and characterization of the ABC superfamily in mus musculus. Genomics (2000) 64:24-31.
17. LING V: Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol. (1997) 40(Suppl.):S3-S8.
18. SCHNEIDER E, PAUL D, IVY P, COWAN KH: Multidrug resistance. Cancer Chemother. Biol. Response Modif. (1999) 18:152-177.
19. SANDOR V, FOJO T, BATES SE: Future perspectives for the development of P-glycoprotein modulators. Drug Resist. Updates (1998) 1:190-200.
20. FISHER GA, LUM BL, HAUSDORFF J, SIKIC BI: Pharmacological considerations in the modulation of multidrug resistance. Eur. J. Cancer (1996) 32A:1082-1088.
21. GIACCONE G, LINN SC, WELINK J et al: A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin. Cancer Res. (1997) 3:2005-2015.
22. FRACASSO PM, WESTERVELDT P, FEARS CA etal: Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.J. Clin. Oncol. (2000) 18:1124.
23. CHAUNCEYTR, RANKIN C, ANDERSON JE etal: A Phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide and the MDR modulator PSC 833: a Southwest Oncology Group study 9617. Leuk. Res. (2000) 24:567-574.
24. ROWINSKY EK, SMITH L, WANG YM et al: Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J. Clin. Oncol. (1998) 16:2964-2976.
25. SPARREBOOM A, PLANTING AS, JEWELL RC etal: Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. AntiCancer Drugs (1999) 10:719-728.
26. DANTZIG AH, SHEPARD RL, LAW KL et al: Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J. Pharmacol. Exp. Ther. (1999) 290:854-862.
27. MARTIN C, BERRIDGE G, MISTRY P et al: The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br. J. Pharmacol. (1999) 128:403-411.
28. NEWMAN MJ, RODARTE JC, ROMANO SJ etal: Preclinical characterization and clinical safety/pharmacokinetics of OC144-093, a novel inhibitor of p-glycoprotein-mediated multidrug resistance. Proc. Amer Assoc. Cancer Res. (1999) 40.
29. STUPP R, BAUER J, PAGANI O et al.: Ventricular arrhythmia and Torsade de Pointe: dose limiting toxicities of the MDR-modulator S9788 in a Phase I trial. Ann. Oncol (1998) 9:1233-1242.
30. VAN ZUYLEN L, SPARREBOOM A, VAN DER GAAST A etal: The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin. Cancer Res. (2000) 6:1365-1371.
31. COLE SPC, BHARDWAJ G, GERLACH JH et al: Overex-pression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (1992) 258:1650-1654.
32. BAKOS E, EVERS R, SZAKACS G et al: Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J. Biol. Chem. (1998) 273:32167-32175.
33. LORICO A, RAPPA G, FLAVELL RA, SARTORELLI AC: Double knockout of the MRP gene leads to increased drug sensitivity invitro. CancerRes. (1996) 56:5351-5355.
34. JEDLITSCHKY G, LEIER I, BUCHHOLZ U, CENTER M, KEPPLER D: ATP-dependent transport of glutathion S-conjugates by multidrug resistance-associated protein. Cancer Res. (1994) 54:4833-4836.
35. JEDLITSCHKY G, LEIER I, BUCHHOLZ U etal: Transport of glutathione, glucuronate and sulfate conjugates by the MRP gene-encoded conjugate exportpump. Cancer Res. (1996) 56:988-994.
36. CHEN ZS, FURUKAWA T, SUMIZAWA T et al.: ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol. Pharmacol. (1999) 55:921-928.
37. HOOIJBERG JH, BROXTERMAN HJ, KOOL M etal: Antifo-late resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. (1999) 59:2532-2535.
38. LOE DW, DEELEY RG, COLE SP: Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res. (1998) 58:5130-5136.
39. HIPFNER DR, DEELEY RG, COLE SP: Structural, mechanistic and clinical aspects of MRP1. Biochim. Biophys. Acta (1999) 1461:359-376.
40. BORST P, EVERS R, KOOL M, WIJNHOLDS J: A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. (2000) 92:1295-1302.
41. RAPPA G, LORICO A, FLAVELL RA, SARTORELLI AC: Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. CancerRes. (1997) 57:5232-5237.
42. SCHINKEL AH, WAGENAAR E, VAN DEEMTER L, MOL CA, BORST P: Absence of the MDR1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A.J. Clin. Invest. (1995) 96:1698-1705.
43. CORDON-CARDO C, O'BRIEN JP, CASALS D et al.: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA (1989) 86:695-698.
44. BEAULIEU E, DEMEULE M, GHITESCU L, BELIVEAU R: P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem. J. (1997) 326 (Pt 2): 539-44.
45. PAULUSMA CC, BOSMA PJ, ZAMAN GJR et al: Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science (1996) 271:1126-1128.
46. SCHINKEL AH: P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv. Rev. (1999) 36:179-194.
47. JONKERJW, WAGENAAR E, VAN DEEMTER Let al: Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug. Br J. Pharmacol (1999) 127:43-50.
48. WIJNHOLDS J, EVERS R, VAN LEUSDEN MR et al.: Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nature Med. (1997) 3:1275-1279.
49. LORICO A, RAPPA G, FINCH RA etal: Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res. (1997) 57:5238-5242.
50. KOOL M, DE HAAS M, SCHEFFER GL et al: Analysis of expression of cMOAT(MRP2), MRP3, MRP4 and MRP5, homologues of the multidrug resistance-associated protein gene in human cancer cell lines. Cancer Res. (1997) 57:3537-3547.
51. BELINSKY MG, KRUH GD: MOAT-E(ARA) is a full-length MRP/cMOAT subfamily transporter expressed in kidney and liver. Br J. Cancer (1999) 80:1342-1349.
52. BELINSKY MG, BAIN LJ, BALSARA BB, TESTA JR, KRUH GD: Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins. J. Natl. Cancer Inst. (1998) 90:1735-1741.
53. BUCHLER M, KONIG J, BROM M etal: cDNAcloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J. Biol. Chem. (1996) 271:15091-15098.
54. TOH S, WADA M, UCHIUMI T etal: Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am. J. Hum. Genet. (1999) 64:739-746.
55. SCHAUB TP, KARTENBECK J, KONIG J et al.: Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J. Am. Soc. Nephrol. (1999) 10:1159-1169.
56. COLE SPC, SPARKS KE, FRASER K et al.: Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. (1994) 54:5902-5910.
57. KOIKE K, KAWABE T, TANAKA T et al.: A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res. (1997) 57:5475-5479.
58. CUI Y, KONIG J, BUCHHOLZ JK et al.: Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. (1999) 55:929-937.
59. MASUDA M, I'IZUKA Y, YAMAZAKI Met al.: Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res. (1997) 57:3506-3510.
60. TANIGUCHI K, WADA M, KOHNO K et al.: A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. (1996) 56:4124-4129.
61. ZENG H, BAIN LJ, BELINSKY MG, KRUH GD: Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res. (1999) 59:5964-5967.
62. KOOL M,VAN DER LINDENM,DE HAAS Met al.:MRP3,an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. USA (1999) 96:6914-6919.
63. ORTIZ DF, LI S, IYER R et al.: MRP3, a new ATP-binding cassette protein localized to the canalicular domain of the hepatocyte. Am. J. Physiol. (1999) 276:G1493-500.
64. KONIGJ,ROSTD, CUI Y, KEPPLERD: Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology (1999) 29:1156-1163.
65. MCALEER MA, BREEN MA, WHITE NL, MATTHEWS N: pABC11(alsoknownasMOAT- CandMRP5),amember of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. J. Biol. Chem. (1999) 274:23541-23548.
66. CHILDS S, YEH RL, GEORGES E, LING V: Identification of a sister gene to P-glycoprotein. Cancer Res. (1995) 55:2029-2034.
67. GERLOFF T, STIEGER B, HAGENBUCH B et al.: The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem. (1998) 273:10046-10050.
68. CHILDS S, YEH RL, HUI D, LING V: Taxol resistance mediated by transfection of the liver-specific sister geneofP-glycoprotein. Cancer Res.(1998) 58:4160-4167.
69. LECUREUR V, SUN D, HARGROVE P et al.: Cloning and expressionofmurine sisterofP-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol. Pharmacol. (2000) 57:24-35.
70. LAING NM, BELINSKY MG, KRUH GDetal.: Amplification of the ATP-binding cassette 2 transporter gene is functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells. Cancer Res. (1998) 58:1332-1337.
71. BROCCARDO C, LUCIANI M, CHIMINI G: The ABCA subclass of mammalian transporters. Biochim. Biophys. Acta. (1999) 1461:395-404.
72. BERGER J, ALBET S, BENTEJAC M et al.: The four murine peroxisomal ABC-transporter genes differ in constitutive, inducible and developmental expression. Eur. J. Biochem. (1999) 265:719-727.
73. MOSSER J, DOUAR AM, SARDE CO et al.: Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature (1993) 361:726-730.
74. CARTIER N, LOPEZ J, MOULLIER P et al.: Retroviral-mediated gene transfer corrects very-long-chain fatty acid metabolism in adrenoleukodystrophy fibroblasts. Proc. Natl. Acad. Sci. USA (1995) 92:1674-1678.
75. SHINNOH N, YAMADA T, YOSHIMURA T et al.: Adreno-leukodystrophy: the restoration of peroxisomal beta-oxidation by transfection of normal cDNA. Biochem. Biophys. Res. Commun. (1995) 210:830-836.
76. LIU LX, JANVIER K, BERTEAUX-LECELLIER V et al.: Homo-and heterodimerization of peroxisomal ATP-binding cassette half-transporters. J. Biol. Chem. (1999) 274:32738-32743.
77. NETIK A, FORSS-PETTER S, HOLZINGER A et al.: Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy. Hum. Mol. Genet. (1999) 8:907-913.
78. ABELE R, TAMPE R: Function of the transport complex TAP in cellular immune recognition. Biochim. Biophys. Acta (1999) 1461:405-419.
79. POWIS SJ, TOWNSEND AR, DEVERSON EV et al.: Restoration of antigen presentation to the mutant cell line RMA-S by an MHC-linked transporter. Nature (1991) 354:528-531.
80. DE LA SALLEH,HANAU D, FRICKER Det al.: Homozygous human TAP peptide transporter mutation inHLA class I deficiency. Science (1994) 265 : 237-41.
81. TEISSERENC H, SCHMITT W, BLAKE N et al.: A case of primary immunodeficiency due to a defect of the major histocompatibility gene complex class I processing and presentation pathway. Immunol. Lett. (1997) 57:183-187.
82. FURUKAWA H, MURATA S, YABE T et al.: Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome. J. Clin. Invest. (1999) 103:755-758.
83. DE LA SALLE H, ZIMMER J, FRICKER D et al.: HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1. J. Clin. Invest. (1999) 103:R9-R13.
84. ARMANDOLA EA, MOMBURG F, NIJENHUIS M et al.: A point mutation in the human transporter associated with antigen processing (TAP2) alters the peptide transport specificity. Eur. J. Immunol. (1996) 26:1748-1755.
85. MOMBURG F, ARMANDOLA EA, POST M, HAMMERLING GJ: Residues in TAP2 peptide transporters controlling substrate specificity. J. Immunol. (1996) 156:1756-1763.
86. ALLIKMETS R, RASKIND WH, HUTCHINSON A et al.: Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum. Mol. Genet. (1999) 8:743-749.
87. CSERE P, LILL R, KISPAL G: Identification of a human mitochondrial ABC transporter, the functional orthologue of yeast Atm1p. FEBS Lett. (1998) 441:266-270.
88. HOGUE DL, LIU L, LING V: Identification and characterization of a mammalian mitochondrial ATP-binding cassette membrane protein. J. Mol. Biol. (1999) 285:379-389.
89. CHEN H, ROSSIER C, LALIOTI MD et al.: Cloning of the cDNA for a human homologue of the Drosophila whitegene and mapping to chromosome 21q22.3. Am. J. Hum. Genet. (1996) 59:66-75.
90. CROOP JM, TILLER GE, FLETCHER JA et al.: Isolation and characterization of a mammalian homolog of the Drosophila white gene. Gene (1997) 185:77-85.
91. MACKENZIE SM, BROOKER MR, GILL TR et al.: Mutations in the white gene of Drosophila melanogaster affecting ABC transporters that determineeyecoloura- tion. Biochim. Biophys. Acta (1999) 1419:173-185.
92. EWART GD, CANNELL D, COX GB, HOWELLS AJ: Mutational analysis of the traffic ATPase (ABC) transporters involved in uptake of eye pigment precursors in Drosophila melanogaster. Implications for structure-function relationships. J. Biol. Chem. (1994) 269:10370-10377.
93. VENKATESWARAN A, REPA JJ, LOBACCARO JM et al.: Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcrip-tional role for specific oxysterols. J. Biol. Chem. (2000) 275:14700-14707.
94. ALLIKMETS R, SCHRIML LM, HUTCHINSON A, ROMANO-SPICA V, DEAN M: A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. (1998) 58:5337-5339.
95. DOYLE LA, YANG W, ABRUZZO LV et al.: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA (1998) 95:15665-15670.
96. MIYAKE K, MICKLEY L, LITMAN T et al: Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. (1999) 59:8-13.
97. DOYLE LA, YANG W, ABRUZZO LE et al: Cloning and characterization of breast cancer resistance protein (BCRP), a novel ATP-binding cassette (ABC) transporter that may contribute to the multidrug-resistance phenotype of MCF-7/AdrVp breast cancer cells. Proc. Amer. Assoc. Cancer Res. (1998) 39.
98. CHEN Y-N, MICKLEY LA, SCHWARTZ AM et al.: Charac terization of Adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J. Biol. Chem. (1990) 265:10073-10080.
99. LEE JS, SCALA S, MATSUMOTO Y et al: Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J. Cell. Biochem. (1997) 65:513-526.
100. YANG C-HJ, HORTON JK, COWAN K, SCHNEIDER E: Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res. (1995) 55:4004-4009.
101. TAYLOR CW, DALTON WS, PARRISH PR et al: Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br. J. Cancer (1991) 63:923-929.
102. NAKAGAWA M, SCHNEIDER E, DIXON KH et al: Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 human breast cancer cells. Cancer Res. (1992) 52:6175-6181.
103. DALTON WS, CRESS AE, ALBERTS DS, TRENT JM: Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Res. (1988) 48:1882-1888.
104. RABINDRANS K, HE H, SINGH M etal: Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res. (1998) 58:5850-5858.
105. HAZLEHURST LA, FOLEY NE, GLEASON-GUZMAN MC et al: Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res. (1999) 59:1021-1028.
106. DIETEL M, ARPS H, LAGE H, NIENDORF A: Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res. (1990) 50:6100-6106.
107. KELLNER U, HUTCHINSON L, SEIDEL A etal: Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein. Int. J. Cancer (1997) 71:817-824.
108. ROSS DD, YANG W, ABRUZZO LV et al: Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl. Cancer Inst (1999) 91:429-433. Phenotype
109. MA J, MALIEPAARD M, NOOTER K et al: Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. Br. J. Cancer (1998) 77:1645-1652.
110. MALIEPAARD M, VAN GASTELEN MA, DE JONG LA et al: Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. (1999) 59:4559-4563.
111. ALLEN JD, BRINKHUIS RF, WIJNHOLDS J, SCHINKEL AH: The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. (1999) 59:4237-4241.
112. LITMAN T, BRANGI M, HUDSON E et al: The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2).J. Cell Sci. (2000) 113:2011-2021.
113. BRANGI M, LITMAN T, CIOTTI M et al: Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR) and potential for glucuronidation in MXR-expressingcells. Cancer Res. (1999) 59:5938-5946.
114. YANG CJ, HORTON JK, COWAN KH, SCHNEIDER E: Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res. (1995) 55:4004-4009.
115. RABINDRAN SK, ROSS DD, DOYLE LA, YANG W, GREENBERGER LM: Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. (2000) 60:47-50.
116. KNUTSEN T, RAO VK, RIED T et al: Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines. Genes Chromosomes Cancer (2000) 27:110-116.
117. MICKLEY LA, SPENGLER BA, KNUTSEN TA, BIEDLER JL, FOJO T: Gene rearrangement: a novel mechanism for MDR-1 gene activation. J. Clin. Invest. (1997) 99:1947-1957.
118. ROCCHI E, KHODJAKOV A, VOLK EL et al: The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem. Biophys. Res. Commun. (2000) 271:42-46.
119. SCHEFFER GL, MAILEPAARD M., PIJNENBORG ACLM et al: Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone-and topotecan-resistant cell lines. Cancer Res. (2000) 60:2589-2593.
120. DE BRUIN M, MIYAKE K, LITMAN T, ROBEY R, BATES SE: Reversal of resistance by GF120918 in cell lines expressingthe ABC half-transporter, MXR. Cancer Lett. (1999) 146:117-126.
121. SCHELGEL S, KLIMECKI W, LIST AF: Breast cancer resistance protein (BCRP) associated drug export and p53 inactivation impact flavopiridol (FLA) antitumor activity. Proc. Amer. Assoc. Cancer Res. (1999) 40.
122. EWART GD, HOWELLS AJ: ABC transporters involved in transport of eye pigment precursors in Drosophila melanogaster. In: Methods in Enzymology (Volume 292). Ambudkar S, Gottesman MM (Eds.) Academic Press, San Diego, USA (1998):213-224.
123. SHANI N, VALLE D: A Saccharomyces cerevisiae homolog of the human adrenoleukodystrophy transporter is a heterodimer of two half ATP-binding cassette transporters. Proc. Natl. Acad. Sci. USA (1996) 93:11901-11906.
124. ROSS DD: Novel mechanisms of drug resistance in leukemia. Leukemia (2000) 14:467-473.
125. ZHOU DC, RAMOND S, VIGUIE F et al: Sequential emergence of MRP-and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines. Int. J. Cancer (1996) 65:365-371.
126. MATSUMOTO Y, TAKANO H, FOJO T: Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype. Cancer Res. (1997) 57:5086-5092.
127. CHEN CC, MEADOWS B, REGIS J et al: Detection of in vivo p-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. Clin Cancer Res. (1997) 4:545-552.
128. BAKKER M, VAN DER GRAAF WT, PIERS DA et al: 99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours. AntiCancer Res. (1999) 19:2349-2353.
129. LUKERG D, FACASSO PM, DOBKINJ, PIWNICA-WORMSD: Modulation of the multidrug resistance p-glycoprotein: detection with technetium-99m-sestamibi in vivo. J. Nucl. Med. (1997) 38:369-372.
130. CHEN WS, LUKER KE, DAHLHEIMER JL et al: Effects of MDR1 and MDR3 P-glycoproteins, MRP1 and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin. Biochem. Pharmacol (2000) 60:413-426.
131. WITHERSPOON SM, EMERSON DL, KERR BM et al: Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res. (1996) 2:7-12.
132. ROBEY R, BAKKE S, STEIN W et al: Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833. Blood (1999) 93:306-314.
133. LEE JS, PAULL K, ALVAREZ M et al.: Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute Drug Screen. Mol. Pharmacol. (1994) 46:627-638.